Claims
- 1. A compound selected from the group of N.sub.1 -acyl-N.sub.2 -phenyl-1,3-diaminopropan-2-ols having the Formula I ##STR14## wherein the acyl group R.sub.1 CO is selected from the group consisting of acetyl, propionyl, butyryl, isobutyryl, valeryl, hexanoyl, 3,3-dimethylacryloyl, 2,2-dimethylpropionyl, isovaleryl, heptanoyl, capryloyl, 2-ethyl-hexanoyl, nonanoyl, hexadecanoyl, octadecanoyl, 6-heptenoyl, 2,4-hexendienoyl, 3-hexenoyl, cyclopropylcarbonyl, cyclobutylcarbonyl, cyclopentylcarbonyl, cyclohexylcarbonyl, 1-methylcyclohexylcarbonyl, cyclohexylacetyl, 3-cyclohexen-1-yl-carbonyl, cycloheptylcarbonyl, 1-adamantylcarbonyl, 1-adamantylacetyl, styoylcarbonyl and 3,4-dimethoxycinnamoyl;
- R.sub.2 represents hydrogen, alkyl containing 1 to 3 carbon atoms, or methoxyethyl, and
- R.sub.3 and R.sub.4 are the same or different from each other and each represent hydrogen, fluorine, chlorine, bromine, iodine, alkyl containing 1 to 3 carbon atoms, or alkoxy containing 1 to 3 carbon atoms; and pharmaceutically acceptable acid addition salts thereof.
- 2. The compound as defined in claim 1, which is N.sub.1 -acetyl-N.sub.2 -methyl-N.sub.2 -phenyl-1,3-diaminopropan-2-ol and its pharmaceutically acceptable acid addition salts.
- 3. The compound as defined in claim 1, which is N.sub.1 -propionyl-N.sub.2 -methyl-N.sub.2 -phenyl-1,3-diaminopropan-2-ol and its pharmaceutically acceptable acid addition salts.
- 4. The compound as defined in claim 1, which is N.sub.1 -butyryl-N.sub.2 -methyl-N.sub.2 -phenyl-1,3-diaminopropan-2-ol and its pharmaceutically acceptable acid addition salts.
- 5. The compound as defined in claim 1, which is N.sub.1 -butyryl-N.sub.2 -methyl-N.sub.2 -(4-fluorophenyl)-1,3-diaminopropan-2-ol and its pharmaceutically acceptable acid addition salts.
- 6. The compound as defined in claim 1, which is N.sub.1 -butyryl-N.sub.2 -methyl-N.sub.2 -(4-chlorophenyl)-1,3-diaminopropan-2-ol and its pharmaceutically acceptable acid addition salts.
- 7. The compound as defined in claim 1, which is N.sub.1 -isobutyryl-N.sub.2 -methyl-N.sub.2 -(4-fluorophenyl)-1,3-diaminopropan-2-ol and its pharmaceutically acceptable acid addition salts.
- 8. The compound as defined in claim 1, which is N.sub.1 -valeryl-N.sub.2 -methyl-N.sub.2 -(4-fluorophenyl)-1,3-diaminopropan-2-ol and its pharmaceutically acceptable acid addition salts.
- 9. The compound as defined in claim 1, which is N.sub.1 -hexanoyl-N.sub.2 -methyl-N.sub.2 -phenyl-1,3-diaminopropan-2-ol and its pharmaceutically acceptable acid addition salts.
- 10. The compound as defined in claim 1, which is N.sub.1 -(3,3-dimethylacryloyl)-N.sub.2 -methyl-N.sub.2 -phenyl-1,3-diaminopropan-2-ol and its pharmaceutically acceptable acid addition salts.
- 11. The compound as defined in claim 1, which is N.sub.1 -(2,2-dimethylpropionyl)-N.sub.2 -methyl-N.sub.2 -phenyl-1,3-diaminopropan-2-ol and its pharmaceutically acceptable acid addition salts.
- 12. The compound as defined in claim 1, which is N.sub.1 -isovaleryl-N.sub.2 -methyl-N.sub.2 -(4-chlorophenyl)-1,3-diaminopropan-2-ol and its pharmaceutically acceptable acid addition salts.
- 13. The compound as defined in claim 1, which is N.sub.1 -hexanoyl-N.sub.2 -methyl-N.sub.2 -(4-chlorophenyl)-1,3-diaminopropan-2-ol and its pharmaceutically acceptable acid addition salts.
- 14. The compound as defined in claim 1, which is N.sub.1 -hexanoyl-N.sub.2 -methyl-N.sub.2 -(4-fluorophenyl)-1,3-diaminopropan-2-ol and its pharmaceutically acceptable acid addition salts.
- 15. The compound as defined in claim 1, which is N.sub.1 -heptanoyl-N.sub.2 -methyl-N.sub.2 -(4-chlorophenyl)-1,3-diaminopropan-2-ol and its pharmaceutically acceptable acid addition salts.
- 16. The compound as defined in claim 1, which is N.sub.1 -capryloyl-N.sub.2 -methyl-N.sub.2 -(4-chlorophenyl)-1,3-diaminopropan-2-ol and its pharmaceutically acceptable acid addition salts.
- 17. The compound as defined in claim 1, which is N.sub.1 -(2-ethylhexanoyl)-N.sub.2 -methyl-N.sub.2 -(4-fluorophenyl)-1,3-diaminopropan-2-ol and its pharmaceutically acceptable acid addition salts.
- 18. The compound as defined in claim 1, which is N.sub.1 -nonanoyl-N.sub.2 -methyl-N.sub.2 -(4-chlorophenyl)-1,3-diaminopropan-2-ol and its pharmaceutically acceptable acid addition salts.
- 19. The compound as defined in claim 1, which is N.sub.1 -hexadecanoyl-N.sub.2 -methyl-N.sub.2 -(4-chlorophenyl)-1,3-diaminopropan-2-ol and its pharmaceutically acceptable acid addition salts.
- 20. The compound as defined in claim 1, which is N.sub.1 -octadecanoyl-N.sub.2 -methyl-N.sub.2 -(4-chlorophenyl)-1,3-diaminopropan-2-ol and its pharmaceutically acceptable acid addition salts.
- 21. The compound as defined in claim 1, which is N.sub.1 -(6-heptenoyl)-N.sub.2 -methyl-N.sub.2 -phenyl-1,3-diaminopropan-2-ol and its pharmaceutically acceptable acid addition salts.
- 22. The compound as defined in claim 1, which is N.sub.1 -(2,4-hexendienoyl-N.sub.2 -methyl-N.sub.2 -phenyl-1,3-diaminopropan-2-ol and its pharmaceutically acceptable acid addition salts.
- 23. The compound as defined in claim 1, which is N.sub.1 -(3-hexanoyl)-N.sub.2 -methyl-N.sub.2 -phenyl-1,3diaminopropan-2-ol and its pharmaceutically acceptable acid addition salts.
- 24. The compound as defined in claim 1, which is N.sub.1 -cyclopropylcarbonyl-N.sub.2 -methyl-N.sub.2 -phenyl-1,3-diaminopropan-2-ol and its pharmaceutically acceptable acid addition salts.
- 25. The compound as defined in claim 1, which is N.sub.1 -cyclobutylcarbonyl-N.sub.2 -methyl-N.sub.2 -phenyl-1,3-diaminopropan-2-ol and its pharmaceutically acceptable acid addition salts.
- 26. The compound as defined in claim 1, which is N.sub.1 -cyclopentylcarbonyl-N.sub.2 -methyl-N.sub.2 -phenyl-1,3-diaminopropan-2-ol and its pharmaceutically acceptable acid addition salts.
- 27. The compound as defined in claim 1, which is N.sub.1 -cyclohexylcarbonyl-N.sub.2 -phenyl-1,3-diaminopropan-2-ol and its pharmaceutically acceptable acid addition salts.
- 28. The compound as defined in claim 1, which is N.sub.1 -cyclohexylcarbonyl-N.sub.2 -(2-methylphenyl)-1,3-diaminopropan-2-ol and its pharmaceuticalldy acceptable acid addition salts.
- 29. The compound as defined in claim 1, which is N.sub.1 -cyclohexylcarbonyl-N.sub.2 -(3-methylphenyl)-1,3-diaminopropan-2-ol and its pharmaceutically acceptable acid addition salts.
- 30. The compound as defined in claim 1, which is N.sub.1 -cyclohexylcarbonyl-N.sub.2 -(2-chlorophenyl)-1,3-diaminopropan-2-ol and its pharmaceutically acceptable acid addition salts.
- 31. The compound as defined in claim 1, which is N.sub.1 -cyclohexylcarbonyl-N.sub.2 -(4-bromophenyl)-1,3-diaminopropan-2-ol and its pharmaceutically acceptable acid addition salts.
- 32. The compound as defined in claim 1, which is N.sub.1 -cyclohexylcarbonyl-N.sub.2 -(3-chloro-2-methylphenyl)-1,3-diaminopropan-2-ol and its pharmaceutically acceptable acid addition salts.
- 33. The compound as defined in claim 1, which is N.sub.1 -cyclohexylcarbonyl-N.sub.2 -(2,6-dimethylphenyl)-1,3-diaminopropan-2-ol and its pharmaceutically acceptable acid addition salts.
- 34. The compound as defined in claim 1, wherein R.sub.1 is cyclohexyl, R.sub.2 is methyl and the ##STR15## is phenyl, 4-methylphenyl, 3-chlorophenyl, 4-chlorophenyl, 4-fluorophenyl, 3,4-dichlorophenyl, 4-methoxyphenyl, or 3,4-dimethoxyphenyl.
- 35. The compound as defined in claim 1, wherein R.sub.1 is cyclohexyl, R.sub.3 and R.sub.4 are hydrogen and R.sub.2 is ethyl, propyl, isopropyl, or methoxyethyl.
- 36. The compound as defined in claim 1, which is N.sub.1 -(1-methylcyclohexylcarbonyl)-N.sub.2 -methyl-N.sub.2 -phenyl-1,3-diaminopropan-2-ol and its pharmaceutically acceptable acid addition salts.
- 37. The compound as defined in claim 1, which is N.sub.1 -cyclohexylacetyl-N.sub.2 -methyl-N.sub.2 -phenyl-1,3-diaminopropan-2-ol and its pharmaceutically acceptable acid addition salts.
- 38. The compound as defined in claim 1, which is N.sub.1 -cyclohexylacetyl-N.sub.2 -methyl-N.sub.2 -(3,4-dichlorophenyl)-1,3-diaminopropan-2-ol and its pharmaceutically acceptable acid addition salts.
- 39. The compound as defined in claim 1, which is N.sub.1 -(3-cyclohexen-1-yl-carbonyl)-N.sub.2 -methyl-N.sub.2 -phenyl-1,3-diaminopropan-2-ol and its pharmaceutically acceptable acid addition salts.
- 40. The compound as defined in claim 1, which is N.sub.1 -cycloheptylcarbonyl-N.sub.2 -methyl-N.sub.2 -phenyl-1,3-diaminopropan-2-ol and its pharmaceutically acceptable acid addition salts.
- 41. The compound as defined in claim 1, which is N.sub.1 -(1-adamantylcarbonyl)-N.sub.2 -methyl-N.sub.2 -phenyl-1,3-diaminopropan-2-ol and its pharmaceutically acceptable acid addition salts.
- 42. The compound as defined in claim 1, which is N.sub.1 -(1-adamantylacetyl)-N.sub.2 -methyl-N.sub.2 -phenyl-1,3-diaminopropan-2-ol and its pharmaceutically acceptable acid addition salts.
- 43. The compound as defined in claim 1, which is N.sub.1 -(1-adamantylacetyl)-N.sub.2 -methyl-N.sub.2 -(4-chlorophenyl)-1,3-diaminopropan-2-ol and its pharmaceutically acceptable acid addition salts.
- 44. The compound as defined in claim 1, wherein R.sub.1 is styryl, R.sub.2 is methyl, and the ##STR16## is phenyl, 4-fluorophenyl, or 4-chlorophenyl.
- 45. The compound as defined in claim 1, which is N.sub.1 -(3,4-dimethoxycinnamoyl)-N.sub.2 -methyl-N.sub.2 -(4-chlorophenyl-1,3-diaminopropan-2-ol and its pharmaceutically acceptable acid addition salts.
- 46. A method of treating disorders which are connected with the formation of ulcers in larger mammals, which comprises the step of administering to a larger mammal an ulcer-inhibiting effective amount of at least one compound, as defined in claim 1.
- 47. The method as defined in claim 46, wherein the amount of the pharmacologically active compound is from about 150 to about 450 mg per day.
Priority Claims (2)
Number |
Date |
Country |
Kind |
2720915 |
May 1977 |
DEX |
|
2720968 |
May 1977 |
DEX |
|
Parent Case Info
This is a continuation of application Ser. No. 067,715 filed Aug. 17, 1979, now abandoned which in turn is a dividsion of Ser. No. 900,998 filed Apr. 28, 1978 now U.S. Pat. No. 4,191,770.
US Referenced Citations (5)
Number |
Name |
Date |
Kind |
2658076 |
Krimmel |
Nov 1953 |
|
3906040 |
Vincent et al. |
Sep 1975 |
|
3998809 |
Milkowski et al. |
Dec 1976 |
|
4059621 |
Vincent et al. |
Nov 1977 |
|
4216167 |
Milkowski et al. |
Aug 1980 |
|
Foreign Referenced Citations (1)
Number |
Date |
Country |
2411885 |
Sep 1974 |
DEX |
Divisions (1)
|
Number |
Date |
Country |
Parent |
900998 |
Apr 1978 |
|
Continuations (1)
|
Number |
Date |
Country |
Parent |
67715 |
Aug 1979 |
|